Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05163080
Title SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)
Acronym SURVIVE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MimiVax, LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Francisco California 94143 United States Details
Miami Cancer Institute Miami Florida 33176 United States Details
Norton Cancer Center Louisville Kentucky 40241 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Atlantic Health Summit New Jersey 07960 United States Details
Roswell Park Comprehensive Cancer Center Buffalo New York 14263 United States Details
NYU Langone Health New York New York 10016 United States Details
Northwell New York New York 10075 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Texas Oncology Austin Texas 78705 United States Details
Fred Hutchinson Cancer Center (FHCC) Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field